<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595813</url>
  </required_header>
  <id_info>
    <org_study_id>IMMUNO-SUP-IPC 2017-002</org_study_id>
    <nct_id>NCT03595813</nct_id>
  </id_info>
  <brief_title>Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy</brief_title>
  <acronym>IMMUNO-SUP</acronym>
  <official_title>Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy-IMMUNO-SUP-IPC 2017-002</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research Center of Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The development of Immune Checkpoint Blockade (ICB) is a revolution in medical oncology as
      ICB have changed the standard treatments of several metastatic tumor types. However, the
      response rate to ICB is low, and the biological bases for this response heterogeneity are
      poorly understood.

      In the frame of Immunosup study, we will collect blood (at baseline, post infusion of ICB
      n°2/4/8 and at progression) and tumor samples (optional: at baseline and progression) from
      patients with locally advanced or metastatic cancer, treated with ICB, in order to determine
      if the dynamics of immunosuppressive actors (MDSC, TReg, Immunosuppressive cytokines)
      predicts response to these immunotherapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Plasma immunosuppressive actors in patients treated with a Checkpoint inhibitor</measure>
    <time_frame>4 months</time_frame>
    <description>Measure (by flux cytometry) and comparison of plasma immunosuppressive actors, between baseline and the 4th injection of an Immune Checkpoint inhibitor</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Lung Cancer Metastatic</condition>
  <condition>Locally Advanced Malignant Neoplasm</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Urologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Patients treated with Immune Checkpoint Blockade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>Blood samples collection (5EDTA vials) at baseline, post infusion of ICB n°2/4/8 and at progression</description>
    <arm_group_label>Patients treated with Immune Checkpoint Blockade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy collection</intervention_name>
    <description>Optional biopsy collection at baseline and progression</description>
    <arm_group_label>Patients treated with Immune Checkpoint Blockade</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Diagnosis of locally advanced or metastatic solid tumor or lymphoma treated with
             Immune check blockade

          -  Signed informed consent

          -  Affiliated to(or beneficiary of) the French Social Security

        Exclusion Criteria:

          -  Pregnant or breastfeeding woman or woman who does not apply effective contraception

          -  Emergency

          -  Vulnerable person or unable to provide informed consent

          -  Emergency

          -  Person unable to comply with required study follow up

          -  Contraindication to the study procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dominique Genre, MD</last_name>
    <phone>+33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jihane Pakradouni, PharmD,PhD</last_name>
    <phone>+33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhône</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Madroszyk, MD</last_name>
      <email>madroszyka@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Madroszyk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune check point blockade</keyword>
  <keyword>biomarkers</keyword>
  <keyword>immunomonitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

